Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer

August 11th 2022

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.

Leukemia Experts Reflect on Defining Moments as Women in the Field

August 8th 2022

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes

August 4th 2022

Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing on treatment decisions, and the need for comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

Wagner Weighs In On Research and Development in Angiosarcoma

July 25th 2022

Michael J. Wagner, MD, talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward, and the potential for immunotherapy in this disease.

FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors

July 21st 2022

Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022

Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.

Jain Discusses the Driving Forces of Gender Inequities in Medicine

July 14th 2022

Dr Jain discusses an article she authored, titled “We’re Running Up the Wrong Side of the Escalator,” which confronts systemic and structural obstacles facing women in medicine.

Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer

July 11th 2022

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Research Reflections: Tarantino Tackles the Implications of ASCO 2022 Data in Breast Cancer

July 7th 2022

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.

Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)

July 4th 2022

Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.

Duma Discusses the Unique Challenges of Women With Lung Cancer

June 30th 2022

Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer

June 23rd 2022

Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the gap in these outcomes.

Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer

June 20th 2022

Dr. Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.

Lee Lays Out Treatment Developments in Non–Clear Cell RCC

June 16th 2022

Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.

Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC

June 13th 2022

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.

Hua Highlights Innovative Research With Immunotherapy in NETs

June 9th 2022

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

June 6th 2022

Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of older adults who develop cancer, and challenges stemming from the COVID-19 pandemic that have affected the care of geriatric patients with cancer, such as the strain put on caregivers and the shift to telemedicine.